NCT03636477 - A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

October 15, 2020

Study Completion Date

June 30, 2021

Conditions

Glioblastoma

Interventions

BIOLOGICAL

Ad-RTS-hIL-12

"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"

DRUG

veledimex

"* 2 doses (10mg/day, 20mg/day)~* 15 oral daily doses of veledimex"

DRUG

Nivolumab

"* 2 doses (1mg/kg, 3mg/kg)~* Every 2 weeks"

Trial Locations (4)

University of Minnesota, Minneapolis

Northwestern Memorial Hospital, Chicago

The University of Texas MD Anderson Cancer Center, Houston

Brigham & Women's Hospital, Boston